ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma

This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), August 2008

Sponsors and Collaborators: North Central Cancer Treatment Group
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00060333
  Purpose

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy after surgery may kill any tumor cells remaining after surgery.

PURPOSE: This phase II trial is studying how well adjuvant radiation therapy works in treating patients who have undergone surgery for desmoplastic melanoma.


Condition Intervention Phase
Melanoma (Skin)
Procedure: adjuvant therapy
Procedure: radiation therapy
Phase II

MedlinePlus related topics:   Cancer    Melanoma   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment
Official Title:   Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Incidence of local recurrence 2 years after completion of study treatment [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Incidence of regional and systemic metastases [ Designated as safety issue: No ]
  • Survival time [ Designated as safety issue: No ]
  • Failure time [ Designated as safety issue: No ]
  • Toxicity [ Designated as safety issue: Yes ]
  • Fatigue as assessed by the Brief Fatigue Inventory [ Designated as safety issue: No ]

Estimated Enrollment:   40
Study Start Date:   July 2003
Estimated Primary Completion Date:   October 2006 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

  • Determine the recurrence rates of patients with desmoplastic melanoma treated with adjuvant radiotherapy after surgical resection.
  • Determine the disease-free and overall survival of patients treated with this regimen.
  • Determine the immediate and long-term morbidity of patients treated with this regimen.

OUTLINE: This is a multicenter study.

Within 8 weeks after surgical resection, patients undergo radiotherapy twice weekly over 2.5 weeks in the absence of unacceptable toxicity.

Patients are followed every 3 months for 2 years and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed desmoplastic melanoma

    • Locally recurrent OR at least 1 mm in depth

      • Recurrent tumor is defined as a tumor found no more than 2 cm from the previous excision or within the surgical bed (which includes the extent of previous skin flaps)
  • Disease resected using standard wide resection or Moh's surgery

    • Histologically negative margins
    • Tumors on proximal extremities must have a 2 cm negative margin
    • Tumors on the head or neck or distal extremities may have margins less than 2 cm provided they are negative
  • No melanoma with focally desmoplastic features, in which the desmoplastic melanoma is not the predominant histologic pattern of the tumor
  • No nondesmoplastic neurotropic or nondesmoplastic spindle cell melanoma
  • No evidence of metastatic disease (local nodal disease allowed)

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • At least 1 year

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Not specified

Other

  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other malignancy within the past 5 years except for the following diseases:

    • Basal cell or squamous cell skin cancer
    • Carcinoma in situ of the cervix
    • Stage I breast cancer adequately treated with adjuvant therapy for which the patient is currently disease-free
    • Stage I or II prostate cancer treated with prostatectomy or radiotherapy with a biochemically-free disease status (i.e., for radical retropubic prostatectomy prostate-specific antigen [PSA] < 0.3 and for radiotherapy PSA < 2.0 above the post-treatment nadir)
  • No nonhealing surgical wound
  • No active infection at the surgical site

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • No concurrent adjuvant immunotherapy

Chemotherapy

  • No concurrent adjuvant chemotherapy

Endocrine therapy

  • Not specified

Radiotherapy

  • No prior radiotherapy to the focused site of this study

Surgery

  • See Disease Characteristics
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00060333

Show 67 study locations  Show 67 Study Locations

Sponsors and Collaborators
North Central Cancer Treatment Group
National Cancer Institute (NCI)

Investigators
Study Chair:     Barbara A. Pockaj, MD     Mayo Clinic Hospital    
Investigator:     John H. Donohue, MD     Mayo Clinic    
Investigator:     Jan L. Kasperbauer, MD     Mayo Clinic    
  More Information


Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site
 

Study ID Numbers:   CDR0000301633, NCCTG-N0275
First Received:   May 6, 2003
Last Updated:   October 22, 2008
ClinicalTrials.gov Identifier:   NCT00060333
Health Authority:   Unspecified

Keywords provided by National Cancer Institute (NCI):
recurrent melanoma  
stage I melanoma  
stage II melanoma  
stage III melanoma  

Study placed in the following topic categories:
Neuroectodermal Tumors
Nevus, Pigmented
Neoplasms, Germ Cell and Embryonal
Neuroepithelioma
Nevus
Recurrence
Neuroendocrine Tumors
Melanoma

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on November 20, 2008




Links to all studies - primarily for crawlers